medigraphic.com
ISSN 0028-3851 (Impreso)

2011, Número 2

<< Anterior Siguiente >>

Rev Neurol Neurocir Psiquiat 2011; 44 (2)


Niveles de glucosa en modelo de rata diabética bajo el uso de olanzapina

Iniestra VE

Idioma: Español
Referencias bibliográficas: 83
Paginas: 57-63
Archivo PDF: 103.30 Kb.


RESUMEN

Objetivo. Cuantificar la glucosa en sangre y el peso generado por la ingesta de olanzapina en ratas diabéticas.
Material y métodos. Se llevó a cabo un estudio experimental (analítico), grupal, prospectivo, incidental. Se hicieron cuantificaciones semanales de glucosa en sangre venosa a 20 ratas sanas y 20 ratas diabéticas seleccionadas en cuatro grupos de diez ratas cada uno organizándose como Grupo 1: ratas sanas. Grupo 2: ratas sanas con olanzapina. Grupo 3, ratas diabéticas; y Grupo 4, ratas diabéticas con olanzapina. El medicamento se administró continuamente por un periodo de cuatro semanas.
Resultados. Se contabilizaron cinco mediciones de peso y cinco de glucosa, iniciando con las basales y una semanal durante cuatro semanas. Se registraron los datos de las variables establecidas, se analizaron los valores mediante tablas representando medias y desviación estándar. Con la prueba T Student se determinó si existieron diferencias significativas ocurridas entre los grupos de experimentación. En los grupos de ratas diabéticas la hiperglicemia fue hasta la cuarta semana en la que se obtuvo una diferencia significativa estadísticamente y en estos dos grupos, en relación con el peso posterior a la primera semana, se hizo evidente una diferencia estadísticamente significativa al obtener un valor de p = 0.0001. En el grupo de ratas diabéticas con olanzapina fueron muriendo los especímenes a partir de la primera semana, logrando sobrevivir tres en la cuarta semana, no encontrándose relación con los más altos niveles de glucosa.
Conclusión. En el modelo de rata diabética que se le dio olanzapina causó hiperglicemia, por lo que se sugiere la contraindicación absoluta del empleo de este antipsicótico en diabéticos debido a que se tiene alta probabilidad de presentar complicaciones con la diabetes conduciendo a la muerte.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Kasanin J. The blood sugar curve in mental disease, II: the schizophrenic (dementia praecox) groups. Arch Neurol Psychiatry 1926; 16: 414-19.

  2. Thonnard-Neumann E. Phenothiazines and diabetes in hospitalized women. Am J Psychiatry 1968; 124: 978-82.

  3. Lerman I. Atención integral del pacente diabético. 3a. Ed. México: Edit. McGraw Hill.

  4. Braceland FJ, Meduna LJ, Vaichulis JA. Delayed action of insulin in schizophrenia. Am J Psychiatry 1945; 102: 108-10.

  5. Dixon L, Weiden P, Delahanty J, Goldberg R, Postrado L, Lucksted A, Lehman A. Prevalence and correlates of diabetes in national schizophrenia samples. Schizophr Bull 2000; 26: 903-12.

  6. Tabata H, Kikuoka M, Kikuoka H, Bessho H, Hirayama J, Hanabusa T, et al. Characteristics of diabetes mellitus in schizophrenic patients. J Med Assoc Thai 1987; 70(Suppl. 2): 90-3.

  7. Mukherjee S, Decina P, Bocola V, Saraceni F, Scapicchio PL. Diabetes mellitus in schizophrenic patients. Compr Psychiatry 1996; 37: 68-73.

  8. Ai D, Roper TA, Riley JA. Diabetic ketoacidosis and clozapine. Postgrad Med J 1998; 74: 493-4.

  9. Colli A, Cocciolo M, Franconbaniera F, Rogantin F, Cattalini N: Diabetic ketoacidosis associated with clozapine treatment (letter). Diabetes Care 1999; 22: 176-7.

  10. Kamran A, Doraiswamy PM, Jane JL, Hammett EB, Dunn L. Severe hyperglycemia associated with high doses of clozapine. Am J Psychiatry 1994; 151: 1395.

  11. Koval MS, Rames LJ, Christie S: Diabetic ketoacidosis associated with clozapine treatment. Am J Psychiatry 1994; 151: 1520-1.

  12. Maule S, Giannela R, Lanzio M, Villari V. Diabetic ketoacidosis with clozapine treatment. Diabetes Nutr Metab 1999; 12: 187-8.

  13. Melkersson KI, Hulting AL, Brismar KE: Different influences of classical antipsychotics and clozapine on glucose-insulin homeostasis in patients with schizophrenia or related psychoses. J Clin Psychiatry 1999; 60: 783-91.

  14. Mohan D, Gordon H, Hindley N, Baker A. Schizophrenia and diabetes mellitus. Br J Psychiatry 1999; 174: 180-1.

  15. Peterson GA, Byrd SL. Diabetic ketoacidosis from clozapine and lithium cotreatment (letter). Am J Psychiatry 1996; 153: 737-8.

  16. Pierides M. Clozapine monotherapy and ketoacidosis. Br J Psychiatry 1997; 171: 90-1.

  17. Popli A, Konicka PE, Jurjus GS, Fuller MA, Jaskiw GE. Clozapine and associated diabetes mellitus. J Clin Psychiatry 1997; 58: 108-11.

  18. Smith H, Kenney-Herbert J, Knowles L. Clozapine induced diabetic ketoacidosis. Aust NZ J Psychiatry 1999; 33: 120-1.

  19. Thompson J, Chengappa KNR, Good CB, Baker RW, Kiewe RP, Bezner J, Schooler NR. Hepatitis, hyperglycemia, pleural effusion, eosinophilia, hematuria and proteinuria occurring early in clozapine treatment. Int Clin Psychopharmacol 1998; 13: 95-8.

  20. Wirshing DA, Spellberg BJ, Erhart SM, Marder SR, Wirshing WC. Novel antipsychotics and new onset diabetes. Biol Psychiatry 1988; 44: 778-83.

  21. Yazici KM, Erbas T, Yazici AH. The effect of clozapine on glucose metabolism. Exp Clin Endocrinol Diabetes 1998; 106: 475-7.

  22. Bettinger TL, Mendelson SC, Dorson PG, Crismon ML. Olanzapine- induced glucose dysregulation. Ann Pharmacother 2000; 34: 865-7.

  23. Fertig MK, Brooks VG, Shelton PS. Hyperglycemia associated with olanzapine. J Clin Psychiatry 1998; 59: 687-9.

  24. Gatta B, Rigalleau V, Gin H. Diabetic ketoacidosis with olanzapine treatment. Diabetes Care 1999; 22: 1002-3.

  25. Goldstein LE, Sporn J, Brown S, Kim H, Finkelstein J, Gaffey GK, Sachs G, Stern TA. New-onset diabetes mellitus and diabetic ketoacidosis associated with olanzapine treatment. Psychosomatics 1999; 40: 438-43.

  26. Hayek DV, Hutll V, Reiss J, Schweiger HD, Fuebl HS: Hyperglycemia and ketoacidosis on olanzapine. Nervenarzt 1999; 70: 836-7.

  27. Melkersson KI, Hulting AL, Brismar KE. Elevated levels of insulin, leptin, and blood lipids in olanzapine-treated patients withschizophrenia or related psychoses. J Clin Psychiatry 2000; 61: 742-9.

  28. Ober SK, Hudak R, Rusterholtz A. Hyperglycemia and olanzapine (letter). Am J Psychiatry 1999; 156: 970.

  29. Procyshyn RM, Pane S, Tse G. New onset diabetes mellitus associated with quetiapine. Can J Psychiatry 2000; 45: 668-9.

  30. Sobel M, Jaggers ED, Franz M: New onset diabetes mellitus associated with initiation of quetiapine treatment. J Clin Psychiatry 1999; 60: 556-7.

  31. Croarkin PE, Jacobs DM, Bain B. Diabetic ketoacidosis associated with risperidone treatment. Psychosomatics 2000; 41: 369-70.

  32. Kostakoglu AE, Yazici KM, Erbas T, Guvener N. Ketoacidosis as a side effect of clozapine: a case report. Acta Psychiatr Scand 1996; 93: 217-18.

  33. Meyer JM. A retrospective comparison of lipid, glucose, and weight changes at one year between olanzapine and risperidone treated inpatients, in Proceedings of the 39th Annual Meeting of the American College of Neuropsychopharmacology. Nashville, Tenn, ACNP, 2000.

  34. Wilson DR, Hammond C, D’Souza L, Sarkar N. New-onset diabetes and ketoacidosis with atypical antipsychotics, in Proceedings of the 39th Annual Meeting of the American College of Neuropsychopharmacology. Nashville, Tenn, ACNP, 2000.

  35. Iqbal N, Oldan RL, Baird G, Schwartz B, Baloy L, Bhagoji B, Simjee M. Diabetes mellitus induced by atypical antipsychotics, in 2000 Annual Meeting Syllabus and Proceedings Summary. Washington, DC: American Psychiatric Association; 2000.

  36. Lindenmayer JP, Nathan A, Smith RC. Hyperglycemia associated with the use of atypical antipsychotics. J Clin Psychiatry 2001; 62(Suppl. 23): 30-8.

  37. Burke JP, Williams K, Gaskill SP, Hazuda HP, Haffner M, Stern MP. Rapid rise in the incidence of type 2 diabetes from 1987 to 1996: results from the San Antonio Heart Study. Arch Intern Med 1999; 159: 1450-6.

  38. Lund BC, Perry PJ, Brooks JM, Arndt S. Clozapine use in patients with schizophrenia and the risk of diabetes, hyperlipidemia, and hypertension. Arch Gen Psychiatry 2001; 58: 1172-6.

  39. Kwong K, Cavazzoni P, Hornbuckle K, Hutchins D, Signa W, Kotsanos J, Breier A. Higher incidences of diabetes mellitus during exposure to antipsychotics-findings from a retrospective cohort study in the US, in Abstracts of the 41st New Clinical Drug Evaluation Unit Meeting. Rockville, Md, National Institute of Mental Health, 2001, poster III-8.

  40. Gianfrancesco F, Grogg A, Mahmaoud R, Markowitz J, Nasrallah HA. Association of new-onset diabetes and antipsychotics: findings from a large health plan database, in Abstracts of the 41st New Clinical Drug Evaluation Unit Meeting. Rockville, Md, National Institute of Mental Health, 2001, poster III-79

  41. Breier A, Kwong K, Hornbuckle K, Cavazonni P, Carlson C, Wu J, Kotsanos J, Holman R: A retrospective cohort study of diabetes mellitus and antipsychotic treatment in the United Kingdom (poster), in Abstracts of the 40th Annual Meeting of the American College of Neuropsychiatry. Nashville, Tenn, ACNP, 2001.

  42. Smith RC, Lindenmayer JP, Khandat A, Wahab M, Bodala P, Rosenberger J. A prospective study of glucose and lipid metabolism with atypical and conventional antipsychotics (poster), in Proceedings of the 14th Annual Research Conference of the New York State Office of Mental Health. Albany, New York State Office of Mental Health, 2001

  43. Volavka J, Czobor P, Sheitman B, Lindenmayer JP, Citrome L, McEvoy JP, Cooper TB, et al. Clozapine, olanzapine, risperidone, and haloperidol in the treatment of patients with chronic schizophrenia and schizoaffective disorder. Am J Psychiatry 2002; 159: 255-62.

  44. Kay SR, Opler LA, Lindenmayer JP. Reliability and validity of the Positive and Negative Syndrome Scale for schizophrenics. Psychiatry Res 1988; 23: 99-110.

  45. Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 2002; 25: S5-S20.

  46. Czobor P, Volavka J, Sheitman B, Lindenmayer JP, Citrome L, McEvoy J, Cooper TB, et al. Antipsychoticinduced weight gain and therapeutic response: a differential association. J Clin Psychopharmacol 2002; 22: 244-51.

  47. Newcomer JW, Haupt DW, Fucetola R, Melson AK, Schweiger JA, Cooper BP, Selke G. Abnormalities in glucose regulation during antipsychotic treatment of schizophrenia. Arch Gen Psychiatry 2002; 59:337–345

  48. Harris MI, Flegal KM, Cowie CC, Eberhardt MS, Goldstein DE, Little RR, Wiedmeyer HM, Byrd-Holt DD: Prevalence of diabetes, impaired fasting glucose and impaired glucose tolerance in US adults. Diabetes Care 1998; 21: 518-24.

  49. Kinon BJ, Basson BR, Gilmore JA, Tollefson GD. Long-term olanzapine treatment: weight change and weight-related health factors in schizophrenia. J Clin Psychiatry 2001; 62: 92-100.

  50. Karenyi C, Lowenstein B. Chlorpromazine induced diabetes. Dis Nerv Syst 1968; 29: 827-8.

  51. Baldessarini RJ, Lipinski JF. Toxicity and side effects of antipsychotic, antimanic, and antidepressant medications. Psychiatr Annals 1976; 6: 484-3.

  52. Boucharlat J, Chatelain R. [An exceptional neuroleptic accident: diabetes insipidus induced by thioridazine.] Annales Medico- Psychologiques 1968; 1: 306 (French).

  53. Baptista T, Lacruz A, Angeles F, Silvera R, de Mendoza S, Mendoza MT, Hernandez L. Endocrine and metabolic abnormalities involved in obesity associated with typical antipsychotic drug administration. Pharmacopsychiatry 2001; 34: 223-31.

  54. Brambilla F, Guastalla A, Guerrini A, Riggi F, Rovere C, Zanoboni A, Zanoboni-Muciaccia W. Glucose-insulin metabolism in chronic schizophrenia. Dis Nerv Syst 1976; 37: 98-103.

  55. Foss MC, Paula FJ, Paccola GM, Piccinato CE. Peripheral glucose metabolism in human hyperprolactinemia. Clin Endocrinol 1995; 43: 721-6.

  56. Schernthaner G, Prager R, Punzengruber C, Luger A: Severe hyperprolactinemia is associated with decreased insulin binding in vitro and insulin resistance in vitro. Diabetologia 1985; 28: 138-42.

  57. Wozniak KM, Linnoila M. Hyperglycemic properties of serotonin receptor antagonists. Life Sci 1991; 49: 101-9.

  58. Henderson DC, Cagliero E, Gray C, Nasrallah RS, Hayden DL, Schoenfeld DA, Goff DC: Clozapine, diabetes mellitus, weight gain, and lipid abnormalities: a five-year naturalistic study. Am J Psychiatry 2000; 157:975–981

  59. Ghaeli P, Dufresne RL. Serum triglyceride levels in patients treated with clozapine. Am J Health System Pharm 1996; 53: 2079-81

  60. Sheitman BB, Bird PM, Binz W, Akinli L, Sanchez C. Olanzapineinduced elevation of plasma triglyceride levels (letter). Am J Psychiatry 1999; 156: 1471-2.

  61. Osser DN, Najarian DM, Dufresne RL. Olanzapine increases weight and serum triglyceride levels. J Clin Psychiatry 1999; 60: 767-70.

  62. Henderson DC. Schizophrenia and comorbid metabolic disorders. J Clin Psychiatry 2005; 66(6 Suppl.): 11-20.

  63. Marder SR, Essock SM, Miller AL, Buchanan RW, Casey DE, Davis JM. Physical health monitoring of patients with schizophrenia. Am J Psychiatry 2004; 161: 1334-49.

  64. De Nayer A, De Hert M, Scheen A, Van Gaal L, Peuskens J, On behalf of the Consensus Group. Belgian consensus on metabolic problems associated with atypical antipsychotics. Int J Psychiatry Clin Pract 2005; 9: 130-7.

  65. Poulin MJ, Cortese L, Williams R, Wine N, McIntyre RS. Atypical antipsychotics in psychiatry practice: practical implications for clinical monitoring. Can J Psychiatry 2005; 50: 555-62.

  66. Cohn TA, Sernyak MJ. Metabolic monitoring for patients treated with antipsychotic medications. Can J Psychiatry 2006; 51: 492-501.

  67. Lean ME, Pajonk FG. Patients on atypical antipsychotic drugs: another high-risk group for type 2 diabetes. Diabetes Care 2003; 26: 1597-605.

  68. Kohen D. Diabetes mellitus and schizophrenia: historical perspective. Br J Psychiatry 2004; 184(Suppl. 47): S64-6.

  69. Regenold WT, Thapar RK, Marano C, Gavirnemi S, Kondapavuluru PV. Increased prevalence of type 2 diabetes mellitus among psychiatric inpatients with bipolar I affective and schizoaffective disorders independent of psychotropic drug use. J Affect Disord 2002; 70: 19-26.

  70. Hedenmalm K, Hagg S, Stahl M, Mortimer O, Spigset O. Glucose intolerance with atypical antipsychotics. Drug Saf 2002; 25: 1107-16.

  71. Melkersson K, Dahl M-L. Adverse metabolic effects associated with atypical antipsychotics. Literature review and clinical implications. Drugs 2004; 64: 701-23.

  72. Newcomer JW, Haupt DW. The metabolic effects of antipsychotic medications. Can J Psychiatry 2006; 51: 480-91.

  73. Koller E, Schneider B, Bennett K, Dubitsky G. Clozapine-associated diabetes. Am J Med 2001; 111: 716-23.

  74. Koller EA, Doraiswamy PM. Olanzapine-associated diabetes mellitus. Pharmacotherapy 2002; 22: 841-52.

  75. Koller EA, Cross JT, Doraiswamy PM, Schneider BS. Risperidone associated diabetes mellitus: a pharmacovigilance study. Pharmacotherapy 2003; 23: 735-44.

  76. Koller EA, Weber J, Doraiswamy PM, Schneider BS. A survey of reports of quetiapine-associated hyperglycemia and diabetes mellitus. J Clin Psychiatry 2004; 65: 857-63.

  77. Koro CE, Fedder DO, L’Italien GJ, Weiss S, Magder LS, Kreyenbuhl J, et al. An assessment of independent effect of olanzapine and risperidone on risk of diabetes among patients with schizophrenia: population based nested case-control study. BMJ 2002; 325: 243-5.

  78. Kornegay CJ, Vasilakis-Scaramozza C, Jick H. Incident diabetes associated with antipsychotic use in the United Kingdom general practice research database. J Clin Psychiatry 2002; 63: 758- 62.

  79. De Hert M, Hanssens L, Van Winkel R, Wampers M, Van Eyck D, Scheen A, et al. Reversibility of antipsychotic treatment-related diabetes in patients with schizophrenia. A case series of switching to aripiprazole. Diabetes Care 2006; 29: 2329-30.

  80. Ader M, Kim SP, Catalano KJ, Ionut V, Hucking K, Richey JM, et al. Metabolic dysregulation with atypical antipsychotics occurs in the absence of underlying disease: a placebo-controlled study of olanzapine and risperidone in dogs. Diabetes 2005; 54: 862-71.

  81. Johnson DE, Yamazaki H, Ward KM, Schmidt AW, Lebel WS, Treadway JL, et al. Inhibitory effects of antipsychotics on carbachol- enhanced insulin secretion from perifused rat islets. Role of muscarinic antagonism in antipsychotic-induced diabetes and hyperglycemia. Diabetes 2005; 54: 1552-8.

  82. Gough S, Pelever R. Diabetes and its prevention: pragmatic solutions for people with schizophrenia. Br J Psychiatr 2004;184: S106-11.

  83. De Hert M, van Eyck D, De Nayer A. Metabolic abnormalities associated with second generation antipsychotics: fact or fiction? Development of guidelines for screening and monitoring. Int Clin Psychopharmacol 2006; 21(Suppl. 2): S11-5.




2020     |     www.medigraphic.com